[Biotherapy and biochemotherapy of patients with malignant melanoma].
OBJECTIVE
To evaluate the efficacy of postoperative biochemotherapy on survival of patients with malignant melanoma.


METHODS
One hundred and five patients with malignant melanoma received postoperative biotherapy/biochemotherapy or radiotherapy/chemotherapy. The median time of follow-up was 3 years (from 1 to 5 years).


RESULTS
The median survival time (MST) in the whole series of patients was 27 months (range: 2-72 months). The MST in patients received postoperative biotherapy/biochemotherapy (57 cases) was 32 months with a 3-year survival rate of 36.8%. That in patients received postoperative radiotherapy/chemotherapy (54 cases) was 20 months.


CONCLUSIONS
Biotherapy/biochemotherapy following surgery may significantly improve survival in patients with malignant melanoma.
Li
Y
Y
Cancer Institute (Hospital), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China.
Qu
F
F
Li
J
J
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D008875:Middle Aged; D011182:Postoperative Care; D016019:Survival Analysis